Fundamentals of Liver Disease

Fundamentals of Liver Disease - Cirrhosis 2.0

Create Account

Availability

On-Demand

9 Courses

Expires on Dec 31, 2025

Cost

$0.00

Credit Offered

4.5 AMA PRA Category 1 Credits

4.5 CE Credits

4.5 ABIM MOC Points

4.5 ABP MOC Points

Description:
Learning Objectives:
Target Audience
Credit Designation
Faculty/Disclosures
Recommended

There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

KEY TOPIC AREAS
Does My Patient Have Cirrhosis?
Natural History of Cirrhosis and General Management of the Compensated Patient
Varices and Variceal Hemorrhage
Ascites
Hyponatremia and Hepatorenal Syndrome
Hepatic Encephalopathy
Infections in Cirrhosis
Pulmonary Complications in the Patient with Cirrhosis
Does my Patient with Cirrhosis Need to be Referred for Liver Transplant?

Release date: July 12, 2021
Review date: August 8, 2024
Expiration date: December 31, 2025
Time to complete each module: 30 minutes

CREDITS OFFERED
Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™
Continuing Education (CE): For a maximum of 4.50 Contact Hour
You may only earn one Continuing Education Credit type - either CME or CE

Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points

COMPONENTS
Online presentations comprised of:
-9 online interactive, narrated modules 20 to 25 minutes in length
-Pre- and post-test questions for each module
-Evaluation for CME or CE credit offering

DIRECTIONS
Click "Register" to activate the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

COPYRIGHT
All faculty in this activity have given their permission for publication ©2021 AASLD.

CONTACT INFORMATION
For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org
For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

• Identify patients with liver disease
• Apply diagnostic tests appropriately
• Discuss important counseling
• Recognize treatment/referral priorities
• Identify first line therapies for different liver diseases
• Refer to specialist in a timely and appropriate fashion

This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

Hepatologists
Gastroenterologists
Nurses
Nurse Practitioners
Pharmacists
Physician Assistants
Transplant Coordinators
Surgeons
Fellows/Trainees
Primary Care Physicians
Other healthcare providers

CREDITS OFFERED
Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™
Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points
Continuing Education (CE): For a maximum of 4.50 Contact Hours

ACCREDITATION AND DESIGNATION STATEMENTS Continuing Medical Education (CME)
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CLAIMING CME CREDITS
Physicians and other health care professionals for a maximum of 4.50 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by July 11, 2024.

CLAIMING ABIM MOC POINTS
Physicians seeking ABIM MOC credit must complete the enduring material by July 11, 2024. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through July 2024 for individuals who successfully complete MOC.

HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

Complete the pre-tests
Watch video presentations
Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)
Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

MOC points are available for ABIM board certified physicians only.

DISCLOSURE OF CONFLICTS OF INTEREST

AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

The faculty, organizers and reviewers have reported the following disclosures:

Patrick Kamath, MD
Faculty
Advisory Committees or Review Panels: Sequana

Guadalupe Garcia-Tsao, MD, FAASLD
Faculty
Nothing to disclose

Juan Abraldes, MD
Faculty
Nothing to disclose

Florence Wong, MD, FRACP, FRCPC
Faculty
Consulting: Sequana

Raimund Pichler, MD
Faculty
Nothing to disclose

Jasmahon Bajaj, MD, MS, FACG, AGAF
Faculty
Advisory Committees or Review Panels: ALF, ACG
Consulting: Salix and Norgine
Grant/Research Support: Grifols, Salix

Puneeta Tandon, MD, FRCPC
Faculty
Nothing to disclose

Michael Fallon, MD
Faculty
Grant/Research Support: Gore

Paul Martin, MD, FAASLD
Faculty
Grant/Research Support: AbbVie, Gilead, Thera, Mallinckrodt, Viking, Durect and Enanta

Amanda J. Chaney, DNP, APRN, FNP-BC
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Royalties: Springer Publishing-Author

Rena Fox, MD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Grant/Research Support: Gilead Sciences

Sonal Kumar, MD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead Sciences, Intercept and AbbVie
Speaker's Bureau: Gilead Sciences and AbbVie
Grant/Research Support: Gilead Sciences, AbbVie and Intercept

Adam Mikolajczyk, MD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

April G. Morris, FNP
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Speaker's Bureau: Gilead, AbbVie, Intercept Pharmaceuticals
Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: AbbVie

Paul Pockros, MD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Amol Rangnekar, MD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Raj Vuppalanchi, MD, FAASLD
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

Susan Zapatka, DNP
Fundamentals of Liver Disease Committee/Organizer/Reviewer
Nothing to disclose

Dominique Clayton
AASLD Staff
Nothing to disclose

Melissa Morrison
AASLD Staff
Nothing to disclose

Melanie Stanton, CAE
AASLD Staff
Nothing to disclose

Sheryl Morgan
Amedco LLC Staff
Nothing to disclose

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Acknowledgement of Commercial Support: No commercial support was received for this enduring material activity.